


GENPHARMASEC
LIMITED
CIN : L24231MH1992PLC323914
(Formerly known as Generic Pharmasec Limited)

Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

+91- 86555 50242

compliance@genpharmasec.com
info@genpharmasec.com

www.genpharmasec.com

Date: 29th January 2024

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.

Ref: Scrip Code: 531592

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Intimation of Incorporation of New wholly owned Subsidiary.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we wish to inform you that the Company has formed a new wholly owned subsidiary company namely Clinigenome India Private Limited.

We are enclosing herewith the information pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular number CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure-A.

For & behalf of the board of Genpharmasec Limited

SOHAN CHATURVEDI
CFO





GENPHARMASEC
LIMITED
CIN : L24231MH1992PLC323914
(Formerly known as Generic Pharmasec Limited)

Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

+91- 86555 50242

compliance@genpharmasec.com
info@genpharmasec.com

www.genpharmasec.com

ANNEXURE A

Disclosure pursuant to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015.

Name of the target entity, details in brief such as size, turnover etc.	Clinigenome India Private Limited The Authorised Share capital of the Company is 2,00,000 Equity Shares of Rs. 10/ each- The paid-up capital of the Company is Rs. 1,00,000/- divided in to 10,000 Equity Shares of Rs. 10 each.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition does not fall within related party transaction(s)
Industry to which the entity being acquired belongs	Specialized Testing Center
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The main objects of Clinigenome India Private Limited as per its MOA is of: To carry on the business of specialized testing centre dedicated to providing high quality molecular testing at affordable price and to promote, establish, maintain, conduct and run testing laboratory, research laboratory, experimental workshops, scientific laboratory, examination, analysis, investigations, test, experiment & research on behalf of government, semi government, local authorities, private bodies and general public for all kinds of materials, including pharmaceuticals, drugs, chemicals, medical, metallurgical, electronic, cement, electrical, agricultural, edibles, and other items of industrial, domestic or commercial use and to buy, sell, import, export, consign, store, clean, recondition & develop or otherwise to deal in all types of intermediates, chemicals, instruments, equipment, apparatuses, accessories, fittings, goods, articles or things which are required for the attainment of the above objects and to provide cargo inspection, survey, sampling facility for export material and insurance purposes.



**GENPHARMASEC
LIMITED**
CIN : L24231MH1992PLC323914
(Formerly known as Generic Pharmasec Limited)

Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East),
Mumbai, Maharashtra, 400101

+91- 86555 50242

compliance@genpharmasec.com
info@genpharmasec.com

www.genpharmasec.com

Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals required for the acquisition.
Indicative time period completion of the acquisition	Not Applicable
Nature of consideration - whether cash consideration or share swap and details of the same	Cash
Cost of acquisition or the price at which the shares are acquired	The Total Cost of acquisition is Rs. 1,00,000/-. [Rs. 1,00,000/- divided in to 10,000 Equity Shares of Rs. 10 each]
Percentage of shareholding / control acquired and / or number of shares acquired	Percentage of shareholding is 100% [Rs. 1,00,000/- divided in to 10,000 Equity Shares of Rs. 10 each]
Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The Company is incorporated as wholly owned subsidiary of the company on 29 th January 2024 History/ Turnover: Not Applicable Country: - India